Limits of early genetic risk prediction

20 years ago, pharmacogenomics was all the buzz: matching specific drugs to our personal DNA was supposed to transform medicine and human health.

But here we are 20 years later, and much of that excitement has fizzled. Very few doctors are actually tailoring their treatments to individual patient DNA in the clinic.

In this special episode, I talk with Dr. Eric Topol, author of the new book Super Agers, about the promise of pharmacogenomics and the new frontiers of medicine. We talk about how he has always put science first - he shares the story of Vioxx, a pain reliever that he was early to see carried massive risks. Eric put his career on the line to let the world know about the problems.